{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-205590","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.757194+00:00","generated_at":"2026-06-12T02:14:14.642279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025","bullets":["FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.","Closed $125M debt facility with OrbiMed; drew $50M, up to $75M additional; cash extends into Q1 2025.","Q2 GAAP net loss $11.0M ($0.24/share) vs $10.2M loss in prior year; non-GAAP loss $9.4M.","Expanding Part 2 enrollment of VP-315 Phase 2 trial for basal cell carcinoma to accelerate development.","Cash and equivalents $55.1M at June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-205590","json":"https://secwatch.observer/filing/0001193125-23-205590.json","markdown":"https://secwatch.observer/filing/0001193125-23-205590.md","text":"https://secwatch.observer/filing/0001193125-23-205590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/d512113d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:14:14.642279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22259be7340845f74780a1b868fc5df9748ba79d","claim":"Verrica Pharmaceuticals Inc. reported financial results for six months ended June 30, 2023.","evidence_excerpt":"Verrica Pharmaceuticals Inc. (the \" Registrant \") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"81675ee33479d437b97cf55f6167874aab49e74c","claim":"Verrica Pharmaceuticals Inc. reported second quarter ended June 30, 2023 results: net income net loss on a GAAP basis was $11.0 million, or $0.24 per share, EPS net loss on a GAAP basis was $11.0 million, or $0.24 per share.","evidence_excerpt":"Verrica Pharmaceuticals Inc. (the \" Registrant \") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss on a GAAP basis was $11.0 million, or $0.24 per share"},{"label":"EPS","value":"net loss on a GAAP basis was $11.0 million, or $0.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}